Exavir Therapeutics Inc.

San Francisco, CA

UEI
EV9JGJL7VVF9
CAGE
9F4N0
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
SAM.gov registration date
Physical address
1506 Golden Gate Ave, San Francisco, CA 94115, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of an ultra-long-acting, self-administered, dolutegravir-based treatment regimen for HIV-1 and HIV-HBV… R44AI195119 National Institute of Allergy and Infectious Diseases (NIH) $998,034
Xvir-110 an ultra-long-acting insti for HIV pre-exposure prophylaxis in IND-enabling studies R44AI179564 National Institute of Allergy and Infectious Diseases (NIH) $4,099,950

Quick answers

Is Exavir Therapeutics Inc. registered in SAM.gov?

Yes. Exavir Therapeutics Inc.'s SAM.gov registration is active through February 11, 2027.

What is Exavir Therapeutics Inc.'s most recent federal award?

Exavir Therapeutics Inc.'s most recent federal grant award is Development of an ultra-long-acting, self-administered, dolutegravir-based treatment regimen for HIV-1 and HIV-HBV… (R44AI195119), from National Institute of Allergy and Infectious Diseases (NIH), on August 4, 2026.

On GovTribe

See Exavir Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login